Tag Archives: XCRA

Top 5 Clean Energy Stocks To Buy Right Now

HDFC Securities’s research report on Tech Mahindra

Tech Mahindra delivered poor revenue growth in 1QFY19 while margin performance was better than expected. Revenue stood at USD 1,224mn (-1.6% QoQ, +0.3% CC), vs our estimate of USD 1,228mn. Enterprise (+1.8%, +3.8% CC QoQ) continue to drive growth led by traction in Manufacturing (+2.5% QoQ) and BFSI (+2.9%). Digital (27% of rev, +30% YoY) is growing in-line with industry average and is driving enterprise growth. Telecom (39.6% of rev, -6.3% QoQ) is dragging overall revenue growth; however management sees it as a seasonal blip and expect recovery form 2QFY19E based on deal wins at the end of the quarter. Deal TCV stands at USD 260mn, out of which ~50% is Telecom.

Outlook

Weve factored USD revenue growth of 7.6/10.6% for FY19/20E, implying revenue CQGR of 3.2/2.2% for FY19/20E and factored EBITDA% at 16.7/17.1%. Maintain BUY with a TP of Rs 740 based on 15x FY20E EPS.

For all recommendations report,click here

Top 5 Clean Energy Stocks To Buy Right Now: Xcerra Corporation(XCRA)

Xcerra Corporation (Xcerra or the Company), formerly known as LTX-Credence Corporation, is a global provider of test and handling capital equipment, interface products, test fixtures and related services to the semiconductor and electronics manufacturing industries. We design, manufacture and market products and services that address the broad, divergent requirements of the mobility, industrial, medical, automotive and consumer end markets, offering a comprehensive portfolio of solutions and technologies, and a global network of strategically deployed applications and support resources. We operate in the semiconductor and electronics manufacturing test markets through our atg-Luther & Maelzer, Everett Charles Technologies (ECT), LTX-Credence and Multitest businesses.   Advisors’ Opinion:

  • [By Garrett Baldwin]

    Get an exclusive invitation to meet Tim before everyone else right here.

    Three Stocks to Watch Today: LC, GE, GS
    General Electric Co. (NYSE: GE) has ousted its CEO John Flannery. Shares are up more than 10% as investors celebrated the news. GE has been mired in a slump, particularly its turbine business. The firm’s new CEO is H. Lawrence Culp, Jr., the former CEO of the industrial firm Danaher. Shares of LendingClub Corp.(NYSE: LC) are under pressure after the SEC charged one of the firm’s divisions with mishandling client money. This weekend, the firm reached a settlement with regulators on charges that the firm inflated its revenue and made changes to products to make the firm look healthier than it is. As a result, the firm’s board of directors forced CEO Renaud Laplanche to resign. Goldman Sachs Group Inc.(NYSE: GS) has replaced CEO Lloyd Blankfein, who has stepped down after more than a decade at the helm at one of Wall Street’s most iconic banks. David Solomon – who has previously served as the firm’s president and COO – will now bet the new CEO. His tenure begins at a tough time for Goldman as the bank struggles with lower trading desk revenues. Look for earnings reports today from Cal-Maine Foods Inc. (NASDAQ: CALM) and Xcerra Corp.(NASDAQ: XCRA).

    Follow Money MorningonFacebook, Twitter, and LinkedIn.

  • [By Rich Smith]

    “Robust industry trends” in the semiconductor industry, argues Davidson, give this “leading provider of semiconductor test handlers and … emerging player in the associated contactor and vision inspection markets” an “ample runway for growth.” Cohu’s also in the process of acquiring one of its top competitors, Xcerra Corporation (NASDAQ:XCRA), in a deal slated to close next quarter, which will add scale to Cohu’s business even as it removes a source of price competition.

  • [By Garrett Baldwin]

    The system that could make you $104,000 richer in the next 12 months…

    Darden Restaurants Inc.(NYSE: DRI) leads a fairly busy day of earnings reports. The restaurant management giant easily topped Wall Street profit numbers by reporting earnings per share of $1.34. The average Wall Street estimate was $1.23. The firm also easily topped revenue expectations. DRI shares were up 4.5% this morning. The problems continue to mount for General Electric Co. (NYSE: GE). This morning, JPMorgan Securities slashed its price target for the U.S. conglomerate from $11 to $10 per share. The investment firm cited ongoing challenges to the company’s turbine business. General Electric has been under pressure since the financial crisis, and it was the worst performing stock on the Dow in 2017 before it was ultimately replaced on the index. Shares of Under Armour Inc. (NYSE: UAA) added 3.4% this morning, but the driver wasn’t necessarily positive for the global apparel giant. According to reports, the Baltimore-based sports apparel giant is cutting 3% of its international workforce. That equates to roughly 400 jobs. The company did raise its fiscal 2018 earnings forecast, and issued a revised update of severance costs. Look for earnings reports from Micron Technology Inc. (NASDAQ: MU), Thor Industries Inc.(NYSE: THO), United Natural Foods Inc.(NASDAQ: UNFI), Steelcase Inc. (NYSE: SCS), Scholastic Corp.(NASDAQ: SCHL), and Xcerra Corp.(NASDAQ: XCRA).

    FollowMoney MorningonFacebook,Twitter, andLinkedIn.

Top 5 Clean Energy Stocks To Buy Right Now: TRACON Pharmaceuticals, Inc.(TCON)

TRACON Pharmaceuticals, Inc., incorporated on October 28, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

TRC105

The Company is developing TRC105 for use in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. VEGF is required for angiogenesis. TRC105 binds to the endoglin receptor at a precise location to inhibit endothelial cell activation and angiogenesis. TRC105 has been studied in over six completed Phase II clinical trials and approximately three completed Phase I clinical trials, and is being dosed in over five Phase II clinical trials. TRC105 is focused on approximately two orphan indications, gestational trophoblastic neoplasia (GTN) and angiosarcoma. The next tier of development includes ongoing Phase II trials in renal cell carcinoma, glioblastoma and hepatocellular carcinoma. The Company has produced formulations of TRC105 for development in ophthalmology, which are developed for the treatment of wet AMD, the cause of blindness in the Western world.

TRC205

The Company’s TRC205 is a humanized, deimmunized anti-endoglin antibody. TRC205 is being developed for the treatment of fibrotic diseases, including nonalcoholic ! steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).

TRC102

The Company is developing TRC102 (methoxyamine hydrochloride) to reverse resistance to specific chemotherapeutics by inhibiting base excision repair (BER). TRC102 interrupts BER by binding within apurinic/apyrimidinic (AP) sites, converting the AP site to a substrate for the enzyme topoisomerase II, which cleaves TRC102-bound deoxy ribonucleic acid (DNA), resulting in an accumulation of DNA strand breaks that trigger cellular apoptosis or programmed cell death. TRC102 is being developed to reverse resistance to Temodar, an alkylating chemotherapeutic, as well as to Alimta and Fludara, two antimetabolite chemotherapeutics. TRC102 began Phase II development through a Phase II clinical trial that combines TRC102 in patients with mesothelioma, as well as a Phase II clinical trial of TRC102 in patients with glioblastoma.

The Company competes with Pfizer, Inc., Acceleron Pharma Inc., Amgen, Inc., MedImmune LLC, OncoMed Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Roche AG, Genfit Corp., Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Galmed Medical Research Ltd., Gilead Sciences, Inc., Immuron Ltd., Shire plc, Mochida Pharmaceutical Co., Ltd., NasVax Ltd., Raptor Pharmaceutical Corp., Takeda Pharmaceutical Company Limited, InterMune, Inc., Boehringer Ingelheim, Biogen Idec., Bristol-Myers Squibb, Celgene Corporation, Fibrogen, Inc., Gilead, Janssen Pharmaceuticals Inc., Novartis AG, Sanofi S.A, Tesaro, Inc. and AbbVie Inc.

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRACON Pharmaceuticals Inc (NASDAQ:TCON) fell 12.3% during trading on Wednesday . The company traded as low as $1.23 and last traded at $1.21. 896,880 shares changed hands during trading, an increase of 112% from the average session volume of 422,831 shares. The stock had previously closed at $1.38.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Buy Right Now: Equity Commonwealth(EQC)

Equity Commonwealth (EQC), incorporated on October 9, 1986, is an internally managed and self-advised real estate investment trust (REIT). The Company is engaged in the ownership and operation primarily of office buildings in central business district (CBD) and suburban locations throughout the United States. The Company’s two reportable segments include CBD properties and suburban properties. As of December 31, 2014, its portfolio included 156 properties (262 buildings) with a combined 42.9 million square feet. The Company’s portfolio consisted of 40 properties (53 buildings) with a combined 21.9 million square feet located in CBD locations and 116 properties (209 buildings) with a combined 21.0 million square feet located in suburban locations. Eleven of its properties (11 buildings) with a combined 1.8 million square feet are located in Australia.

As on December 31, 2014, the Company had real estate investments in 156 properties (262 buildings) that were leased to approximately 1,800 tenants and 85.8% of the Company’s total square feet were leased. The Company’s principal source of funds for its operations is rents from tenants at its properties. Its tenants include Office Depot, Inc., Expedia, Inc., John Wiley & Sons, Inc, Telstra Corporation Limited, PNC Financial Services Group, United States Government, Royal Dutch Shell plc, J.P. Morgan Chase & Co., Flextronics International Ltd., United Healthcare Services Inc., The Bank of New York Mellon Corp., Carmike Cinemas, Inc., Bankers Life and Casualty Company, Jones Day, Wells Fargo & Co, Level 3 Communications, Inc., Towers Watson & Co, Ballard Spahr LLP and RE/MAX Holdings, Inc.

Advisors’ Opinion:

  • [By Tim Melvin]

    Zell is the Chairman of Equity Commonwealth (NYSE: EQC), an office REIT that he and some activist investors took over back in 2014.

    His management team has spent the last five years selling what they consider to be non-core properties.

  • [By Shane Hupp]

    Ffcm LLC increased its position in Equity Commonwealth (NYSE:EQC) by 97.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 39,928 shares of the real estate investment trust’s stock after acquiring an additional 19,711 shares during the quarter. Ffcm LLC’s holdings in Equity Commonwealth were worth $1,198,000 at the end of the most recent quarter.

  • [By Matthew DiLallo]

    Equity Commonwealth (NYSE:EQC) continued the steady pare-down of its property portfolio during the fourth quarter, ending the year with only 10 remaining real estate assets. However, for the first time in years, the company’s funds from operations increased as it was able to more than offset the lost income with gains elsewhere. But it’s not yet clear whether the company’s earnings growth will continue, since it has several more property sales in the works, which could weigh on its results until it starts making acquisitions.

Top 5 Clean Energy Stocks To Buy Right Now: Fisher(j)

James Fisher and Sons plc, together with its subsidiaries, provides marine services and specialist engineering services in the United Kingdom, Ireland, Norway, and internationally. The company operates through four segments: Specialist Technical Services, Offshore Oil Services, Defence, and Marine Oil. The Specialist Technical Services engages in the hire and sale of large scale pneumatic fenders; provision of ship to ship transfer services; and design and supply of systems for monitoring strains and stress in structures and equipment. This segment also offers non-destructive testing services; and design, engineering, and manufacturing services for the nuclear decommissioning industries. The Offshore Oil Services segment manufactures and rents equipment for the offshore oil and gas industry; and designs and manufactures specialist down hole tools and equipment for extracting oil. This segment also offers related specialist labor, such as cranes, winches and pumps to the of fshore sector, wind farms, and for subsea operations. The Defence segment designs, constructs, and operates submarine rescue vehicles and remotely operated vehicles; and operates surface ships. It offers marine services to the Ministry of Defence (MoD) and other navies, including the United Kingdom; maintenance, asset management, and consultancy services; military strategic sealift capability through its operation of six roll on ? roll off vessels for the MoD; and submarine rescue services to the government of Singapore. The Marine Oil segment is involved in the sea transportation of clean petroleum products in north west Europe; and wharf operations. The company was founded in 1847 and is headquartered in Barrow-in-Furness, the United Kingdom.

Advisors’ Opinion:

  • [By Logan Wallace]

    Joincoin (CURRENCY:J) traded 22.3% higher against the dollar during the 1 day period ending at 9:00 AM E.T. on October 2nd. Joincoin has a total market capitalization of $95,205.00 and $22.00 worth of Joincoin was traded on exchanges in the last 24 hours. During the last seven days, Joincoin has traded 6.1% lower against the dollar. One Joincoin coin can now be bought for approximately $0.0299 or 0.00000456 BTC on major cryptocurrency exchanges.

  • [By Logan Wallace]

    Joincoin (CURRENCY:J) traded 12.5% higher against the dollar during the 24-hour period ending at 10:00 AM ET on September 30th. Joincoin has a market cap of $98,508.00 and $17.00 worth of Joincoin was traded on exchanges in the last day. One Joincoin coin can now be bought for $0.0309 or 0.00000467 BTC on popular exchanges. During the last seven days, Joincoin has traded 8.2% lower against the dollar.

  • [By Shane Hupp]

    Joincoin (J) is a proof-of-work (PoW) coin that uses the Multiple hashing algorithm. Its launch date was August 13th, 2014. Joincoin’s total supply is 3,173,702 coins. Joincoin’s official website is bitcointalk.org/index.php?topic=737405.0. Joincoin’s official Twitter account is @Joincoin_Team.

  • [By Joseph Griffin]

    Joincoin (CURRENCY:J) traded 1.7% lower against the U.S. dollar during the 24 hour period ending at 0:00 AM ET on May 8th. Joincoin has a total market cap of $145,714.00 and $7.00 worth of Joincoin was traded on exchanges in the last 24 hours. During the last week, Joincoin has traded up 28.6% against the U.S. dollar. One Joincoin coin can currently be bought for about $0.0471 or 0.00000521 BTC on cryptocurrency exchanges.

Top 5 Clean Energy Stocks To Buy Right Now: Marathon Oil Corporation(MRO)

Marathon Oil Corporation, through its subsidiaries, operates as an international energy company with operations in the United States, Canada, Africa, the Middle East, and Europe. It operates through three segments: Exploration and Production, Oil Sands Mining, and Integrated Gas. The Exploration and Production segment explores for, produces, and markets liquid hydrocarbons and natural gas. The Oil Sands Mining segment mines, extracts, and transports bitumen from oil sands deposits in Alberta, Canada; and upgrades the bitumen to produce and market synthetic crude oil and vacuum gas oil. The Integrated Gas segment markets and transports products manufactured from natural gas, such as liquified natural gas and methanol. The company was formerly known as USX Corporation and changed its name to Marathon Oil Corporation in July 2001. Marathon Oil Corporation was founded in 1887 and is based in Houston, Texas.

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Marathon Oil (NYSE:MRO) based its 2019 plans on oil averaging $50 a barrel. At that price point, the company can fund its $2.6 billion capital spending plan — enough money to grow its U.S. oil production by 12% this year — and its dividend with plenty of room to spare. Marathon has so much breathing room that it can fund its 2019 budget as well as its dividend at $45 oil, which means it’s on track to produce a gusher of free cash now that oil is in the mid-$50s. Marathon currently expects to return the bulk of that money to shareholders through additional share repurchases, which sets up investors to potentially earn some high-octane total returns this year if oil keeps going higher.

  • [By Matthew DiLallo]

    Marathon Oil (NYSE:MRO) delivered exceptional operational and financial results in 2018. Not only did its U.S. oil production outperformthe midpoint of its initial guidance range by 22.5%, but it also generated a boatload of free cash flow. That strong performance is one of many reasons Marathon CEO Lee Tillman believes his company checks all the boxes for investors. He laid out the case for the company on itsfourth-quarter conference call, detailing four reasons Marathon is an ideal oil stock. Here’s what he said.

Top 10 Clean Energy Stocks To Watch Right Now

Things are moving fast in renewable energy. Really fast. Consider that in 2008 wind farms supplied just 1.5% of all electricity in the United States. But by 2019 wind power is expected to contribute 6.9% of American electricity and overtake hydropower as the top renewable energy source.

The rise of wind power wouldn’t have been possible without two companies in particular, which combine to own 20.7 gigawatts of wind capacity, or about 24% of the country’s total. Investors wouldn’t be surprised to learn that clean energy provider NextEra Energy is one of the renewable energy stocks most important to American wind power. However, the relatively unheard of natural gas and electric utility Xcel Energy (NASDAQ:XEL) doesn’t seem to garner nearly the same level of attention. Overlooking it could be a mistake.

With 10-year total returns of 226% and plans to grow its dividend and EPS at annual clips of 5% to 7% — all while investing billions in new wind and solar capacity — it could be the best renewable energy stock you’ve never heard of.

Top 10 Clean Energy Stocks To Watch Right Now: AVEO Pharmaceuticals, Inc.(AVEO)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By George Budwell]

    Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) gained a healthy 10.7% last month, according to data from S&P Global Market Intelligence. The spark?

  • [By Shane Hupp]

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s share price traded down 24.2% during mid-day trading on Tuesday . The company traded as low as $2.15 and last traded at $2.16. 9,547,354 shares traded hands during trading, an increase of 395% from the average session volume of 1,930,275 shares. The stock had previously closed at $2.85.

  • [By Joseph Griffin]

    These are some of the media headlines that may have impacted Accern’s scoring:

    Get AVEO Pharmaceuticals alerts:

    Deadline Upcoming in $15 Million Settlement in the AVEO Pharmaceuticals Inc (NASDAQ:AVEO) Investor Lawsuit (digitaljournal.com) $1.35 Million in Sales Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter (americanbankingnews.com) AVEO Pharmaceuticals, Inc. (AVEO) Expected to Announce Earnings of -$0.06 Per Share (americanbankingnews.com) Equity Opportunities Iv Growth Purchases 236,479 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock (americanbankingnews.com) AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Buys $392,301.27 in Stock (americanbankingnews.com)

    Several analysts recently weighed in on the company. Zacks Investment Research raised AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, May 4th. BidaskClub raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 24th. Finally, ValuEngine raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.05.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Clean Energy Stocks To Watch Right Now: Blueprint Medicines Corporation(BPMC)

Advisors’ Opinion:

  • [By Todd Campbell]

    After clinical-stage competitor Loxo Oncology (NASDAQ:LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ:BPMC) tumbled by as much as 16% on Monday.

  • [By Shane Hupp]

    A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC acquired a new position in Blueprint Medicines in the 4th quarter valued at about $173,000. First Mercantile Trust Co. acquired a new position in Blueprint Medicines in the 4th quarter valued at about $183,000. Tower Research Capital LLC TRC grew its position in Blueprint Medicines by 942.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new position in Blueprint Medicines in the 4th quarter valued at about $227,000. 97.79% of the stock is owned by institutional investors.

    COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades Blueprint Medicines (BPMC) to Hold” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at www.tickerreport.com/banking-finance/3356624/bidaskclub-downgrades-blueprint-medicines-bpmc-to-hold.html.

    Blueprint Medicines Company Profile

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    ValuEngine downgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a strong-buy rating to a buy rating in a report issued on Monday morning.

    BPMC has been the topic of a number of other reports. JMP Securities lowered their price target on Blueprint Medicines from $109.00 to $103.00 and set a buy rating on the stock in a research report on Monday, June 4th. Zacks Investment Research upgraded Blueprint Medicines from a sell rating to a hold rating in a research report on Tuesday, July 3rd. BidaskClub upgraded Blueprint Medicines from a sell rating to a hold rating in a research report on Friday, August 3rd. Finally, Cowen reiterated a buy rating on shares of Blueprint Medicines in a research report on Wednesday, August 1st. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $91.80.

Top 10 Clean Energy Stocks To Watch Right Now: Natural Health Trends Corp.(NHTC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

  • [By Shane Hupp]

    Natural Health Trends (NASDAQ:NHTC) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

  • [By Max Byerly]

    Central Garden & Pet (NASDAQ: CENT) and Natural Health Trends (NASDAQ:NHTC) are both consumer discretionary companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Top 10 Clean Energy Stocks To Watch Right Now: Xcerra Corporation(XCRA)

Advisors’ Opinion:

  • [By Max Byerly]

    LTX-Credence Co. common stock (NASDAQ:XCRA) – Analysts at B. Riley increased their FY2018 earnings per share estimates for LTX-Credence Co. common stock in a research note issued on Tuesday, May 29th. B. Riley analyst C. Ellis now forecasts that the semiconductor company will post earnings of $1.03 per share for the year, up from their prior estimate of $0.99. B. Riley has a “Neutral” rating and a $14.00 price objective on the stock. B. Riley also issued estimates for LTX-Credence Co. common stock’s Q4 2018 earnings at $0.27 EPS, Q1 2019 earnings at $0.27 EPS, Q2 2019 earnings at $0.23 EPS, Q3 2019 earnings at $0.28 EPS, Q4 2019 earnings at $0.32 EPS, FY2019 earnings at $1.09 EPS and FY2020 earnings at $1.30 EPS.

  • [By Rich Smith]

    “Robust industry trends” in the semiconductor industry, argues Davidson, give this “leading provider of semiconductor test handlers and … emerging player in the associated contactor and vision inspection markets” an “ample runway for growth.” Cohu’s also in the process of acquiring one of its top competitors, Xcerra Corporation (NASDAQ:XCRA), in a deal slated to close next quarter, which will add scale to Cohu’s business even as it removes a source of price competition.

  • [By Ethan Ryder]

    These are some of the news headlines that may have effected Accern Sentiment’s scoring:

    Get LTX-Credence Co. common stock alerts:

    LTX-Credence Co. common stock (XCRA) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com) Why Xcerra (XCRA) Could Beat Earnings Estimates Again (finance.yahoo.com) Cohu, Inc. — Moody’s rates Cohu’s CFR at B1; new Senior Secured Term Loan B at B1; outlook stable (finance.yahoo.com) Brokerages Expect LTX-Credence Co. common stock (XCRA) Will Announce Earnings of $0.28 Per Share (americanbankingnews.com)

    XCRA traded down $0.13 during midday trading on Friday, reaching $14.00. The company’s stock had a trading volume of 315,922 shares, compared to its average volume of 270,685. The firm has a market capitalization of $768.81 million, a P/E ratio of 28.57, a price-to-earnings-growth ratio of 1.06 and a beta of 1.46. The company has a quick ratio of 3.35, a current ratio of 4.40 and a debt-to-equity ratio of 0.01. LTX-Credence Co. common stock has a twelve month low of $9.50 and a twelve month high of $14.87.

  • [By Garrett Baldwin]

    Get an exclusive invitation to meet Tim before everyone else right here.

    Three Stocks to Watch Today: LC, GE, GS
    General Electric Co. (NYSE: GE) has ousted its CEO John Flannery. Shares are up more than 10% as investors celebrated the news. GE has been mired in a slump, particularly its turbine business. The firm’s new CEO is H. Lawrence Culp, Jr., the former CEO of the industrial firm Danaher. Shares of LendingClub Corp. (NYSE: LC) are under pressure after the SEC charged one of the firm’s divisions with mishandling client money. This weekend, the firm reached a settlement with regulators on charges that the firm inflated its revenue and made changes to products to make the firm look healthier than it is. As a result, the firm’s board of directors forced CEO Renaud Laplanche to resign. Goldman Sachs Group Inc. (NYSE: GS) has replaced CEO Lloyd Blankfein, who has stepped down after more than a decade at the helm at one of Wall Street’s most iconic banks. David Solomon – who has previously served as the firm’s president and COO – will now bet the new CEO. His tenure begins at a tough time for Goldman as the bank struggles with lower trading desk revenues. Look for earnings reports today from Cal-Maine Foods Inc. (NASDAQ: CALM) and Xcerra Corp. (NASDAQ: XCRA).

    Follow Money Morning on Facebook, Twitter, and LinkedIn.

Top 10 Clean Energy Stocks To Watch Right Now: Equity Commonwealth(EQC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Neuberger Berman Group LLC lowered its stake in HRPT Properties Trust (NYSE:EQC) by 62.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,127 shares of the real estate investment trust’s stock after selling 15,165 shares during the period. Neuberger Berman Group LLC’s holdings in HRPT Properties Trust were worth $307,000 at the end of the most recent quarter.

  • [By ]

    1. Equity Commonwealth (NYSE: EQC)
    It may be surprising to find a real estate investment trust (REIT) on this list, but Sam Zell’s investment vehicle is preparing itself for a possible debt bomb. Zell’s ability to foresee economic trends has built him great wealth. Now, he is selling EQC’s holdings to create a cash hoard ready to deploy when debt causes real estate prices to plunge again.  

  • [By Matthew DiLallo]

    Equity Commonwealth (NYSE:EQC) continued to steadily sell off its portfolio of real estate holdings, closing three more sales during the quarter, bringing its property count down to 13. As a result, cash flow kept declining. That trend doesn’t show any signs of ending given that the company has more properties on the market and doesn’t yet see a good opportunity to make acquisitions. 

  • [By Stephan Byrd]

    HRPT Properties Trust (NYSE:EQC) had its price target boosted by investment analysts at JMP Securities to $33.00 in a report issued on Tuesday. The brokerage currently has a “market outperform” rating on the real estate investment trust’s stock. JMP Securities’ target price points to a potential upside of 4.04% from the company’s previous close.

Top 10 Clean Energy Stocks To Watch Right Now: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) CEO Adelene Q. Perkins sold 5,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $2.82, for a total transaction of $14,100.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

  • [By Logan Wallace]

    ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a report published on Saturday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Clean Energy Stocks To Watch Right Now: Argo Pantes Tbk PT (ARGO)

Advisors’ Opinion:

  • [By Max Byerly]

    These are some of the news stories that may have impacted Accern’s rankings:

    Get Argo Group alerts:

    Cosgrave Property Group is close to selling its Liberty Shopping Centre in London (thetimes.co.uk) Form 4 Argo Group International For: Sep 05 Filed by: Bullock Jay Stanley (streetinsider.com) Insider Selling: Argo Group (ARGO) CFO Sells 12,323 Shares of Stock (americanbankingnews.com) Argo Blockchain touts promise of cryptos despite falling prices (stockmarketwire.com) Argo Blockchain shrugs off crypto slide and looks long term (proactiveinvestors.co.uk)

    Shares of ARGO traded down $0.30 during midday trading on Friday, hitting $62.95. The stock had a trading volume of 47,644 shares, compared to its average volume of 126,574. Argo Group has a fifty-two week low of $49.69 and a fifty-two week high of $65.90.

  • [By Logan Wallace]

    These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

    Get Argo Group alerts:

    Labour Day game against Tiger-Cats pivotal for Argonauts’ playoff chances (torontosun.com) Argo Group (ARGO) Director John R. Power, Jr. Sells 5,355 Shares (americanbankingnews.com) Keeping supermarket risks in check is a slippery business (insurancebusinessmag.com) Video: ‘Sea Change’ Highlights Female Sailors (bernews.com) Argo names new US specialty programmes leader (intelligentinsurer.com)

    ARGO has been the topic of several research analyst reports. Zacks Investment Research cut shares of Argo Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 10th. Raymond James upped their price target on shares of Argo Group from $65.00 to $68.00 and gave the stock a “strong-buy” rating in a report on Tuesday, May 8th. Finally, Keefe, Bruyette & Woods upped their price target on shares of Argo Group to $69.00 and gave the stock an “outperform” rating in a report on Tuesday, August 7th.

Top 10 Clean Energy Stocks To Watch Right Now: CHS Inc(CHSCL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    CHS (NASDAQ:CHSCL) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Top 10 Clean Energy Stocks To Watch Right Now: Jewett-Cameron Trading Company(JCTCF)

Advisors’ Opinion:

  • [By Max Byerly]

    Media headlines about Jewett-Cameron Trading (NASDAQ:JCTCF) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jewett-Cameron Trading earned a news impact score of 0.08 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.2200105194978 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Ethan Ryder]

    Jewett-Cameron Trading Company Ltd (NASDAQ:JCTCF) Director Donald M. Boone sold 3,097 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $8.59, for a total value of $26,603.23. Following the completion of the sale, the director now directly owns 1,326,242 shares of the company’s stock, valued at $11,392,418.78. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

  • [By Ethan Ryder]

    Jewett-Cameron Trading Co (NASDAQ:JCTCF) Director Donald M. Boone sold 4,401 shares of the company’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $7.89, for a total transaction of $34,723.89. Following the sale, the director now directly owns 1,369,743 shares of the company’s stock, valued at $10,807,272.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Top 10 Clean Energy Stocks To Watch Right Now: BP Prudhoe Bay Royalty Trust(BPT)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market had a tumultuous session on Wednesday, as major benchmarks started the day weak but bounced back in the afternoon. Investors weren’t happy with the current state of geopolitical uncertainty, with trade disputes threatening to become larger problems than ever. But the release of the minutes of the latest meeting of the Federal Reserve’s monetary policy committee convinced many that the central bank will be slow to do lasting damage to the economic expansion, remaining measured in the pace of its interest rate increases. Moreover, some companies had good news that sent their shares higher. Tiffany (NYSE:TIF), BP Prudhoe Bay Royalty Trust (NYSE:BPT), and Ralph Lauren (NYSE:RL) were among the best performers on the day. Here’s why they did so well.

  • [By Max Byerly]

    Blockport (CURRENCY:BPT) traded down 4.1% against the dollar during the 1 day period ending at 23:00 PM ET on August 12th. In the last week, Blockport has traded down 26.3% against the dollar. One Blockport token can now be bought for $0.0894 or 0.00001414 BTC on exchanges including Kucoin and IDEX. Blockport has a market capitalization of $4.73 million and approximately $7,133.00 worth of Blockport was traded on exchanges in the last 24 hours.

  • [By Ethan Ryder]

    Blockport (CURRENCY:BPT) traded down 0.3% against the U.S. dollar during the 1-day period ending at 23:00 PM ET on September 14th. One Blockport token can now be bought for $0.0819 or 0.00001261 BTC on popular cryptocurrency exchanges including Kucoin and IDEX. Over the last week, Blockport has traded down 2.3% against the U.S. dollar. Blockport has a total market cap of $4.33 million and $60,265.00 worth of Blockport was traded on exchanges in the last 24 hours.

Hot Medical Stocks To Buy Right Now

Verition Fund Management LLC acquired a new stake in shares of ICU Medical, Incorporated (NASDAQ:ICUI) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 935 shares of the medical instruments supplier’s stock, valued at approximately $236,000.

A number of other institutional investors also recently modified their holdings of ICUI. Point72 Asset Management L.P. increased its position in ICU Medical by 65.0% during the 1st quarter. Point72 Asset Management L.P. now owns 200,256 shares of the medical instruments supplier’s stock valued at $50,545,000 after purchasing an additional 78,856 shares during the period. BlackRock Inc. grew its position in shares of ICU Medical by 3.4% in the 4th quarter. BlackRock Inc. now owns 1,879,874 shares of the medical instruments supplier’s stock worth $406,052,000 after buying an additional 62,605 shares during the period. Redmile Group LLC grew its position in shares of ICU Medical by 38.2% in the 1st quarter. Redmile Group LLC now owns 193,472 shares of the medical instruments supplier’s stock worth $48,832,000 after buying an additional 53,500 shares during the period. Castleark Management LLC grew its position in shares of ICU Medical by 3,016.5% in the 4th quarter. Castleark Management LLC now owns 51,110 shares of the medical instruments supplier’s stock worth $11,040,000 after buying an additional 49,470 shares during the period. Finally, Northern Trust Corp grew its position in shares of ICU Medical by 21.3% in the 1st quarter. Northern Trust Corp now owns 246,976 shares of the medical instruments supplier’s stock worth $62,337,000 after buying an additional 43,410 shares during the period. 72.22% of the stock is currently owned by institutional investors and hedge funds.

Hot Medical Stocks To Buy Right Now: American Superconductor Corporation(AMSC)

Advisors’ Opinion:

  • [By Money Morning News Team]

    American Superconductor Corp.(Nasdaq: AMSC), based in Massachusetts, manufactures two-megawatt wind turbines and supplies for the construction of electrical power grids.

  • [By Shane Hupp]

    American Superconductor (NASDAQ:AMSC) had its price target upped by investment analysts at B. Riley from $6.00 to $7.00 in a research note issued on Monday. The firm presently has a “neutral” rating on the technology company’s stock. B. Riley’s price objective suggests a potential upside of 10.06% from the company’s current price.

Hot Medical Stocks To Buy Right Now: Xcerra Corporation(XCRA)

Advisors’ Opinion:

  • [By Max Byerly]

    Element Capital Management LLC acquired a new stake in LTX-Credence Co. common stock (NASDAQ:XCRA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,132 shares of the semiconductor company’s stock, valued at approximately $141,000.

  • [By Max Byerly]

    LTX-Credence Co. common stock (NASDAQ:XCRA) – Analysts at B. Riley increased their FY2018 earnings per share estimates for LTX-Credence Co. common stock in a research note issued on Tuesday, May 29th. B. Riley analyst C. Ellis now forecasts that the semiconductor company will post earnings of $1.03 per share for the year, up from their prior estimate of $0.99. B. Riley has a “Neutral” rating and a $14.00 price objective on the stock. B. Riley also issued estimates for LTX-Credence Co. common stock’s Q4 2018 earnings at $0.27 EPS, Q1 2019 earnings at $0.27 EPS, Q2 2019 earnings at $0.23 EPS, Q3 2019 earnings at $0.28 EPS, Q4 2019 earnings at $0.32 EPS, FY2019 earnings at $1.09 EPS and FY2020 earnings at $1.30 EPS.

Hot Medical Stocks To Buy Right Now: Toro Company (TTC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Toro (TTC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Toro (NYSE:TTC) last posted its quarterly earnings data on Thursday, May 24th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.18 by $0.02. The firm had revenue of $875.30 million during the quarter, compared to analyst estimates of $901.26 million. Toro had a return on equity of 45.89% and a net margin of 10.08%. Toro’s revenue was up .3% on a year-over-year basis. During the same period in the prior year, the business posted $1.08 EPS. equities research analysts expect that Toro will post 2.71 earnings per share for the current fiscal year.

  • [By Logan Wallace]

    Toro (NYSE:TTC) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

  • [By Shane Hupp]

    Toro (NYSE:TTC) – Dougherty & Co cut their Q2 2018 earnings per share (EPS) estimates for Toro in a report issued on Tuesday, May 22nd. Dougherty & Co analyst J. Fisher now expects that the company will post earnings of $1.18 per share for the quarter, down from their previous estimate of $1.22.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Best Buy Co., Inc. (NYSE: BBY) is projected to report quarterly earnings at $0.74 per share on revenue of $8.73 billion.
    McKesson Corporation (NYSE: MCK) is expected to report quarterly earnings at $3.56 per share on revenue of $51.25 billion.
    Medtronic plc (NYSE: MDT) is estimated to report quarterly earnings at $1.39 per share on revenue of $8.00 billion.
    Hormel Foods Corporation (NYSE: HRL) is projected to report quarterly earnings at $0.45 per share on revenue of $2.39 billion.
    Brady Corporation (NYSE: BRC) is expected to report quarterly earnings at $0.49 per share on revenue of $291.47 million.
    Sanderson Farms, Inc. (NASDAQ: SAFM) is projected to report quarterly earnings at $2.2 per share on revenue of $841.75 million.
    The Toronto-Dominion Bank (NYSE: TD) is estimated to report quarterly earnings at $1.16 per share on revenue of $6.86 billion.
    Royal Bank of Canada (NYSE: RY) is expected to report quarterly earnings at $1.61 per share on revenue of $8.05 billion.
    58.com Inc. (NYSE: WUBA) is projected to report quarterly earnings at $0.21 per share on revenue of $372.49 million.
    Luxoft Holding, Inc. (NYSE: LXFT) is estimated to report quarterly earnings at $0.59 per share on revenue of $228.53 million.
    The Toro Company (NYSE: TTC) is expected to report quarterly earnings at $1.21 per share on revenue of $916.73 million.
    StealthGas Inc. (NASDAQ: GASS) is projected to report quarterly earnings at $0.06 per share on revenue of $37.75 million.
    Stage Stores, Inc. (NYSE: SSI) is estimated to report earnings for its first quarter.
    Thermon Group Holdings, Inc. (NYSE: THR) is projected to report quarterly earnings at $0.2 per share on revenue of $96.24 million.
    Tuniu Corporation (NASDAQ: TOUR) is estimated to report quarterly loss at $0.03 per share on revenue of $76.72 million.

     

Hot Medical Stocks To Buy Right Now: McDermott International, Inc.(MDR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on McDermott International (MDR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Zacks]

    On the news front, U.S. supermajor Chevron Corp. (NYSE: CVX) gave its go-ahead to the $5.1 billion second stage of its massive Gorgon LNG project in Western Australia, while oilfield service providers McDermott International, Inc. (NYSE: MDR) and National Oilwell Varco, Inc. (NYSE: NOV) provided first-quarter operational updates.

  • [By Motley Fool Staff]

    In this segment from the MarketFoolerypodcast, host Chris Hill is joined once again by Million Dollar Portfolio’s Jason Moser, and Stock Advisor Canada’s Taylor Muckerman to talk about the latest news around McDermott International(NYSE:MDR), which spurned a buyout offer from fellow oil and gas engineering firm Subsea 7.

  • [By Dan Caplinger]

    Wall Street started the week on a muted note on Monday, as major benchmarks generally closed slightly down. Much of the attention among investors was on the bond market, where 10-year Treasury yields rose as high as 2.99%, signaling to some the possibility of much higher financing costs that could punish companies that overextended their balance sheets with debt when rates were much lower. Yet some individual companies had good news that sent their shares higher. McDermott International (NYSE:MDR), Box (NYSE:BOX), and Hanesbrands (NYSE:HBI) were among the best performers on the day. Here’s why they did so well.

Hot Medical Stocks To Buy Right Now: Colony NorthStar, Inc. (CLNS)

Advisors’ Opinion:

  • [By Paul Ausick]

    Colony NorthStar Inc. (NYSE: CLNS) traded down about 2.5% Wednesday and posted a new 52-week low of $9.86 after closing Tuesday at $10.11. The 52-week high is $14.74. Volume was over 7.7 million, about double the daily average of 3.5 million shares. The company had no specific news.

  • [By Ethan Ryder]

    Verition Fund Management LLC acquired a new position in Colony NorthStar (NYSE:CLNS) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 52,863 shares of the real estate investment trust’s stock, valued at approximately $297,000.

  • [By Stephan Byrd]

    NorthStar Realty Europe Corp. is a European focused commercial real estate company with predominately prime office properties within key cities in Germany, the United Kingdom and France, organized as a REIT and managed by an affiliate of Colony NorthStar, Inc (NYSE: CLNS), a leading global equity REIT with an embedded investment management platform.